Wound Biologics Market Size To Reach $4.8 Billion By 2033

August 2026 | Report Format: Electronic (PDF)

Wound Biologics Market Growth & Trends

The global wound biologics market size is expected to reach USD 4.8 billion by 2033, registering a CAGR of 8.1% from 2026 to 2033, according to a new report by Grand View Research, Inc. The rising geriatric population, introduction of technologically advanced products, and increasing cases of burns are the key driving factors for this market.

The wound biologic therapy helps in restoring innate repair mechanisms of the patients. It also involves application of active biological agents such as plant-derived biomolecules. These biological agents has antimicrobial, anti-inflammatory attributes, and antioxidant properties that helps in rapid healing of wounds. In addition, the biologic dressing restricts water, electrolyte, protein, and heat loss and allows minimal risk of contamination. It also enables autolytic debridement and develop a granular wound bed, thereby promoting rapid wound healing.

The wound biologics treatment is very much effective in healing chronic and acute wounds. The increasing cases of burn wounds and diabetic foot ulcers across the globe are anticipated to be the major driving factor for this market growth. For instance, as per a report published by the National Center for Biotechnology Information (NCBI), in 2019, the global prevalence of Diabetic Foot Ulcers (DFU) was 6.3% in 2018 and North America reported the highest DFU prevalence rate of 13.0% and Oceania had the lowest prevalence of 3.0%. Since, wound biologics allows rapid and effective healing, thus increasing incidence of chronic wounds are expected to surge the demand for wound biologics products, thereby propelling the market growth over the forecast period.

Request a free sample copy or view report summary: Wound Biologics Market Report

Wound Biologics Market Report Highlights

By product, the biological skin substitutes held the largest revenue share of 64.9% in 2025. The topical agents segment is expected to grow significantly over the forecast period.
By application, the chronic wounds held the largest revenue share of 59.8% in 2025. The acute wounds segment is expected to grow at the fastest CAGR during the forecast period.
By end-use, the hospitals held the largest revenue share of 45.4% in 2025. The ambulatory surgical centers (ASCs) segment is expected to grow at the fastest CAGR during the forecast period.
North America dominated the wound biologics market with the largest revenue share of 43.5% in 2025. The U.S. wound biologics industry held the largest share of North America in 2025.